论文部分内容阅读
目的:探讨将抗中性粒细胞胞浆抗体(ANCA)作为检测指标,对于抗中性粒细胞胞浆抗体相关疾病诊断治疗中的临床应用价值。方法:随机抽取我院在2010年1月-2014年12月收治的400例抗中性粒细胞胞浆抗体相关疾病患者为研究对象进行ANCA检测,并以100例健康者作为对比。结果:在抽取的400例患者中,肾病综合征、韦格纳氏肉芽肿、系统性红斑狼疮、未分类血管炎、急性肾炎及慢性肾炎患者进行ANCA检测的阳性率分别为39.8%,85.6%,66.7%,60.0%,40.0%,14.4%,但100例健康者的检测结果中未能发现抗中性粒细胞胞浆抗体存在。结论:将抗中性粒细胞胞浆抗体作为检测指标,可以对中性粒细胞胞浆抗体相关疾病的有效诊断以及其他疾病的治疗和预后有较高的临床应用价值。
Objective: To investigate the clinical value of anti-neutrophil cytoplasmic antibody (ANCA) as a detection index in the diagnosis and treatment of anti-neutrophil cytoplasmic antibody-related diseases. Methods: A total of 400 anti-neutrophil cytoplasmic antibody-related diseases in our hospital from January 2010 to December 2014 were randomly selected as the study subjects for ANCA and 100 healthy controls were compared. Results: The positive rates of ANCA in patients with nephrotic syndrome, Wegener’s granulomatosis, systemic lupus erythematosus, unclassified vasculitis, acute nephritis and chronic nephritis were 39.8% and 85.6% respectively in the extracted 400 patients, , 66.7%, 60.0%, 40.0% and 14.4%, respectively. However, no detectable anti-neutrophil cytoplasmic antibodies were detected in 100 healthy controls. CONCLUSIONS: Using anti-neutrophil cytoplasmic antibody as a detection index can have a high clinical value for the effective diagnosis of neutrophil cytoplasmic antibody-related diseases and for the treatment and prognosis of other diseases.